http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 06 Aug 2026 16:01:38 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/Lineage+Cell+Therapeutics+%28LCTX%29+Misses+Q2+EPS+by+1c/26883284.html <p>Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $1.07 million versus the consensus estimate of $4.57 million.</p> <p>For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=LCTX">click here</a>.</p> http://www.streetinsider.com/Earnings/Lineage+Cell+Therapeutics+%28LCTX%29+Misses+Q2+EPS+by+1c/26883284.html Thu, 06 Aug 2026 16:01:38 -0400 LCTX http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1)</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD As Founding Member</b> </li> <li> <b>Cash, cash equivalents, and marketable securities as of June 30, 2026 expected to support planned operations into Q3 2028.</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54584501&amp;newsitemid=20260806053201&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ecb3a436fed1ba7b7ff45e07f59e4343" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its second quarter 2026 financial http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26883254.html Thu, 06 Aug 2026 16:01:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54575980&amp;newsitemid=20260730404175&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=1c8a199f509dc559878277f929532255" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2026 financial and operating results and to provide a business update.</p><p http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html Thu, 30 Jul 2026 08:00:00 -0400 LCTX LCTX O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54575980&amp;newsitemid=20260730404175&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=1c8a199f509dc559878277f929532255" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2026 financial and operating results and to provide a business update.</p><p http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html Thu, 30 Jul 2026 08:00:00 -0400 LCTX LCTX O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54575980&amp;newsitemid=20260730404175&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=1c8a199f509dc559878277f929532255" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2026 financial and operating results and to provide a business update.</p><p http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html Thu, 30 Jul 2026 08:00:00 -0400 LCTX LCTX O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54575980&amp;newsitemid=20260730404175&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=1c8a199f509dc559878277f929532255" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2026 financial and operating results and to provide a business update.</p><p http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html Thu, 30 Jul 2026 08:00:00 -0400 LCTX LCTX O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54575980&amp;newsitemid=20260730404175&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=1c8a199f509dc559878277f929532255" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2026 financial and operating results and to provide a business update.</p><p http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html Thu, 30 Jul 2026 08:00:00 -0400 LCTX LCTX O.02770996 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)--</p> <p style="text-align:justify"><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54575980&amp;newsitemid=20260730404175&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=1c8a199f509dc559878277f929532255" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2026 financial and operating results and to provide a business update.</p><p http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+to+Report+Second+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+August+6%2C+2026/26839122.html Thu, 30 Jul 2026 08:00:00 -0400 LCTX LCTX O.02770996 http://www.streetinsider.com/Corporate+News/Lineage+Cell+Therapeutics+updates+COR1+corneal+cell+therapy+program/26760091.html <p>Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) provided an update on its COR1 program, an allogeneic corneal endothelial cell (CEnC) transplant therapy in preclinical development for corneal endothelial disease.</p><p>The company said it has manufactured corneal endothelial cells using its AlloSCOPE platform that meet internal thresholds for potency, identity, and scale. Lineage said it will advance COR1 into in-vivo animal testing, with initial data expected later this year.</p><p>COR1 uses a "thaw-and-inject" formulation designed to allow cryopreserved storage and immediate use. The program employs the company's AlloSCOPE 5D manufacturing process, which uses bioreactor-based expansion and differentiation. Lineage said its two-tiered http://www.streetinsider.com/Corporate+News/Lineage+Cell+Therapeutics+updates+COR1+corneal+cell+therapy+program/26760091.html Mon, 13 Jul 2026 08:00:58 -0400 LCTX http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html <p class="bwalignc"> <b>Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT</b> </p><ul class="bwlistdisc"> <li> <b>COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease</b> </li> <li> <b>Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation</b> </li> <li> <b>Proprietary “Thaw and Inject (TAI)” Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage</b> </li> <li> <b>Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced Cells</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54568450&amp;newsitemid=20260713449564&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=509e3b06b1595c04db5374140f8a1d93" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off http://www.streetinsider.com/Press+Releases/Lineage+Provides+Update+on+COR1+Cell+Therapy+Program+for+Corneal+Endothelial+Disease/26760042.html Mon, 13 Jul 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996